These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19215676)

  • 1. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?
    Tuzun Y; Celik Y; Bayan K; Yilmaz S; Dursun M; Canoruc F
    J Int Med Res; 2009; 37(1):79-86. PubMed ID: 19215676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers.
    Tuzun Y; Yilmaz S; Dursun M; Canoruc F; Celik Y; Cil T; Boyraz T
    J Int Med Res; 2009; 37(1):87-95. PubMed ID: 19215677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Assessment of Two Strategies for Interpreting Tumor Markers in Ascitic Effusions.
    Trapé J; Sant F; Montesinos J; Arnau A; Sala M; Figols C; Franquesa J; Esteve-Valverde E; Pérez R; Aligué J; Catot S; Casado E; Domenech M; Trapé-Ubeda J; Bergós C; Vida F; Sort P; Bonet M; Ruiz D; González-Fernández C; Ordeig J; Molina R
    In Vivo; 2020; 34(2):715-722. PubMed ID: 32111775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
    Zhu FL; Ling AS; Wei Q; Ma J; Lu G
    Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a variety of biological parameters in distinguishing cirrhotic from malignant ascites.
    Alexandrakis MG; Moschandrea J; Kyriakou DS; Alexandraki R; Kouroumalis E
    Int J Biol Markers; 2001; 16(1):45-9. PubMed ID: 11288954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic algorithm based on ratio of ascites-serum tumor markers is superior to tumor markers in the differentiation of benign ascites from malignant ascites.
    Liu M; Zhang N; Wei X; Xiao Z; Song Y; Du L
    Am J Med Sci; 2024 Oct; 368(4):361-368. PubMed ID: 38880300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites.
    Chen SJ; Wang SS; Lu CW; Chao Y; Lee FY; Lee SD; Wu SL; Cherng KL; Lo KJ
    J Gastroenterol Hepatol; 1994; 9(4):396-400. PubMed ID: 7948823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation.
    Kaleta EJ; Tolan NV; Ness KA; O'Kane D; Algeciras-Schimnich A
    Clin Biochem; 2013 Jun; 46(9):814-8. PubMed ID: 23454392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites.
    Trapé J; Gurt G; Franquesa J; Montesinos J; Arnau A; Sala M; Sant F; Casado E; Ordeig JM; Bergos C; Vida F; Sort P; Isava Á; González M; Molina R
    Anticancer Res; 2015 Oct; 35(10):5655-60. PubMed ID: 26408739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites.
    Liu F; Kong X; Dou Q; Ye J; Xu D; Shang H; Xu K; Song Y
    Ann Hepatol; 2014; 13(3):357-63. PubMed ID: 24756011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tumour markers in patients with chronic kidney disease.
    Xiaofang Y; Yue Z; Xialian X; Zhibin Y
    Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
    Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
    Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASCITIC AND SERUM LEVELS OF TUMOR BIOMARKERS (CA 72-4, CA 19-9, CEA AND CA 125) IN DISCRIMINATION OF CAUSE OF ASCITES: A PROSPECTIVE STUDY.
    Jain T; Ram S; Kumar H; Saroch A; Sharma V; Singh H
    Arq Gastroenterol; 2022; 59(2):198-203. PubMed ID: 35830029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein and insulin-like growth factor-1 in differential diagnosis of ascites.
    Abdel-Razik A; Eldars W; Elhelaly R; Elzehery R
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1868-1873. PubMed ID: 27010362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results.
    Antonangelo L; Sales RK; Corá AP; Acencio MM; Teixeira LR; Vargas FS
    Curr Oncol; 2015 Oct; 22(5):e336-41. PubMed ID: 26628873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites.
    Jung M; Jeung HC; Lee SS; Park JY; Hong S; Lee SH; Noh SH; Chung HC; Rha SY
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):517-26. PubMed ID: 19774395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods.
    Bala L; Sharma A; Yellapa RK; Roy R; Choudhuri G; Khetrapal CL
    NMR Biomed; 2008 Jul; 21(6):606-14. PubMed ID: 18205245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules.
    Bekci TT; Senol T; Maden E
    J Int Med Res; 2009; 37(2):438-45. PubMed ID: 19383238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of ascitic soluble human leukocyte antigen-G for distinguishing malignant ascites from benign ascites.
    Sun J; Chang YX; Niu CY
    Tumour Biol; 2017 Nov; 39(11):1010428317726840. PubMed ID: 29130388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.